Ad
Search
Generic filters
Filter by content type
Taxonomy terms

BLCM – Bellicum Pharmaceuticals Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 5

Low: 5

High: 5

Total Analysts: 1

Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. Its product candidates include BPX-601 and BPX-603. BPX-601, is an autologous GoCAR-T product candidate containing inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). BPX-603 is its dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses